Program
ENN0403
A development code. Also written as “ENN0403, low dose”, “ENN0403, high dose” and “ENN0403 capsules, low dose”.
Its studies are mostly in Macular Edema · Acute Kidney Injury, led by EnnovaBio.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| EnnovaBio | 31 open or running | phase 2since Sep 29, 2024 | Aug 9, 2022 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 9, 2022First study: phase 1 study in HealthyFirst studyNCT05506540 · 69 enrolled · Australia
- Sep 29, 2024Phase 2 study in Cardiac Surgery Associated - Acute Kidney InjuryNCT06632613 · 200 planned · China
- Nov 25, 2024Phase 2 study in Diabetic Macular Edema (DME)NCT06708260 · 60 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06708260Diabetic Macular Edema (DME) · China | 2 | Completed | Aug 12, 2026 | 60 |
| NCT06632613Cardiac Surgery Associated - Acute Kidney Injury · China | 2 | Recruiting | Feb 2026 | 200 |
| NCT05506540Healthy · Australia | 1 | Completed | May 16, 2022 | 69 |
How it is read
Names in the registry
- “ENN0403, low dose”, 1 entry
- “ENN0403, high dose”, 1 entry
- “ENN0403 capsules, low dose”, 1 entry
- “ENN0403 capsules, high dose”, 1 entry
- “ENN0403 1mg”, 1 entry
Codes read as this program: ENN0403.
Conditions, from the studies’ own filings
- Macular Edema, 1 study
- Acute Kidney Injury, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.